UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1152) 1152
science & technology (1092) 1092
life sciences & biomedicine (1013) 1013
aminopyridines - therapeutic use (821) 821
animals (649) 649
aminopyridines - pharmacology (628) 628
male (614) 614
female (577) 577
pharmacology & pharmacy (336) 336
middle aged (302) 302
mice (284) 284
adult (267) 267
aminopyridines - administration & dosage (264) 264
aminopyridines - adverse effects (237) 237
benzamides - therapeutic use (226) 226
aged (217) 217
rats (216) 216
oncology (213) 213
cyclopropanes - therapeutic use (177) 177
dose-response relationship, drug (172) 172
neurosciences & neurology (171) 171
treatment outcome (161) 161
abridged index medicus (158) 158
pulmonary disease, chronic obstructive - drug therapy (158) 158
cell line, tumor (144) 144
neurosciences (138) 138
research (136) 136
benzamides - pharmacology (135) 135
mutation (133) 133
respiratory system (132) 132
disease models, animal (126) 126
roflumilast (122) 122
care and treatment (121) 121
aminopyridines - pharmacokinetics (120) 120
drug therapy (117) 117
kinases (115) 115
amrinone (114) 114
analysis (114) 114
cyclopropanes - pharmacology (107) 107
phosphodiesterase 4 inhibitors - therapeutic use (105) 105
cancer (103) 103
double-blind method (102) 102
aminopyridines - chemistry (101) 101
breast neoplasms - drug therapy (101) 101
rats, sprague-dawley (95) 95
4-aminopyridine (93) 93
administration, oral (93) 93
heart failure - drug therapy (93) 93
general & internal medicine (88) 88
quinolones - therapeutic use (88) 88
breast cancer (87) 87
cystic fibrosis - drug therapy (87) 87
research article (87) 87
aminopyridines (86) 86
cell biology (86) 86
cell proliferation - drug effects (86) 86
drug therapy, combination (86) 86
antineoplastic agents - pharmacology (85) 85
benzodioxoles - therapeutic use (85) 85
proteins (85) 85
chronic obstructive pulmonary disease (83) 83
antineoplastic agents - therapeutic use (82) 82
cardiotonic agents - therapeutic use (82) 82
time factors (82) 82
clinical trials (81) 81
benzamides - adverse effects (80) 80
mice, inbred c57bl (80) 80
adolescent (79) 79
medicine & public health (78) 78
science & technology - other topics (78) 78
aminophenols - therapeutic use (77) 77
clinical trials as topic (77) 77
multidisciplinary sciences (77) 77
cystic fibrosis transmembrane conductance regulator - genetics (76) 76
tumors (76) 76
young adult (76) 76
cystic fibrosis (74) 74
signal transduction - drug effects (74) 74
clinical neurology (73) 73
cyclopropanes - adverse effects (73) 73
rodents (73) 73
antineoplastic combined chemotherapy protocols - therapeutic use (72) 72
dosage and administration (72) 72
indoles - pharmacology (71) 71
inflammation (71) 71
biochemistry & molecular biology (70) 70
morpholines - pharmacology (69) 69
xenograft model antitumor assays (69) 69
cystic fibrosis - genetics (67) 67
psychiatry (67) 67
cyclin-dependent kinase 4 - antagonists & inhibitors (66) 66
protein kinase inhibitors - pharmacology (66) 66
benzamides - administration & dosage (65) 65
breast neoplasms - pathology (65) 65
gene expression (65) 65
medicine (65) 65
phosphodiesterase inhibitors - therapeutic use (65) 65
apoptosis - drug effects (64) 64
cyclin-dependent kinase 6 - antagonists & inhibitors (64) 64
health aspects (64) 64
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1478) 1478
German (47) 47
Spanish (15) 15
Japanese (14) 14
Russian (14) 14
French (10) 10
Chinese (8) 8
Italian (6) 6
Polish (2) 2
Romanian (2) 2
Turkish (2) 2
Ukrainian (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Bian, X and Gao, J and Luo, F and Rui, C and Zheng, T and Wang, D and Wang, Y and Roberts, T M and Liu, P and Zhao, J J and Cheng, H
Oncogene, ISSN 1476-5594, 09/2017, Volume 37, Issue 3, pp. 341 - 351
Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising cancer therapeutics especially for tumors with deficient homologous recombination (HR) repair... 
Biochemistry & Molecular Biology | Oncology | Genetics & Heredity | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Humans | Endometrium - drug effects | Spheroids, Cellular - pathology | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neoplasms, Experimental - pathology | Aminopyridines - therapeutic use | Endometrial Neoplasms - genetics | Neoplasms, Experimental - genetics | Female | Spheroids, Cellular - drug effects | Recombinational DNA Repair - drug effects | Morpholines - therapeutic use | PTEN Phosphohydrolase - genetics | Carcinoma, Endometrioid - genetics | PTEN Phosphohydrolase - deficiency | Morpholines - pharmacology | Mice, Transgenic | Piperazines - therapeutic use | Carcinoma, Endometrioid - drug therapy | Piperazines - pharmacology | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Phthalazines - therapeutic use | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aminopyridines - pharmacology | CRISPR-Cas Systems | Cell Line, Tumor | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Endometrium - pathology | Neoplasms, Experimental - drug therapy | Carcinoma, Endometrioid - pathology | Prevention | Phosphatases | Endometrial cancer | DNA damage | Therapeutics | Genetic aspects | Health aspects | Sugars | Cancer | Monosaccharides | Homeopathy | Materia medica and therapeutics | CRISPR | Tensin | Phosphorylation | BRCA1 protein | Homologous recombination | Poly(ADP-ribose) polymerase | RNA polymerase | Double-strand break repair | Kinases | DNA repair | 1-Phosphatidylinositol 3-kinase | DNA-dependent protein kinase | Ribose | Rodents | Non-homologous end joining | Tumor suppressor genes | PTEN protein | Deoxyribonucleic acid--DNA | Endometrium | Tumors | Index Medicus | Original
Journal Article
Cell reports (Cambridge), ISSN 2211-1247, 05/2017, Volume 19, Issue 8, pp. 1669 - 1684
Although non-small cell lung cancer (NSCLC) patients benefit from standard taxane-platin chemotherapy, many relapse, developing drug resistance. We established... 
lung cancer | histone methylation | taxane-platin chemotherapy | JIB-04 | GSK-J4 | KDM | histone demethylases | demethylase inhibitors | Jumonji demethylases | drug resistance | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Lung Neoplasms - drug therapy | Transcription, Genetic - drug effects | Taxoids - pharmacology | Benzazepines - adverse effects | Humans | Aminopyridines - adverse effects | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Taxoids - therapeutic use | Hydrazones - adverse effects | Aminopyridines - therapeutic use | Carboplatin - therapeutic use | Hydrazones - therapeutic use | Jumonji Domain-Containing Histone Demethylases - antagonists & inhibitors | Bridged-Ring Compounds - pharmacology | Neoadjuvant Therapy | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Bridged-Ring Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Enzyme Inhibitors - pharmacology | Benzazepines - pharmacology | Pyrimidines - pharmacology | Enzyme Inhibitors - therapeutic use | Hydrazones - pharmacology | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Animals | Benzazepines - therapeutic use | Pyrimidines - therapeutic use | Aminopyridines - pharmacology | Pyrimidines - adverse effects | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Histones - metabolism | Carboplatin - pharmacology | Methylation | Jumonji Domain-Containing Histone Demethylases - metabolism | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Cancer, ISSN 1097-0142, 07/2019, Volume 125, Issue 18, pp. 3121 - 3130
Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by... 
acute myeloid leukemia (AML) | clinical trials | complete remission | measurable residual disease (MRD) | Life Sciences & Biomedicine | Oncology | Science & Technology | Triazines - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Decitabine | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Transplantation, Homologous | Pyrrolidines - therapeutic use | Neoplasm, Residual | Molecular Diagnostic Techniques | Flow Cytometry | Aminopyridines - therapeutic use | Azacitidine | Cytogenetic Analysis | Leukemia, Myeloid, Acute - therapy | Triazoles - therapeutic use | Hydrazines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Hematopoietic Stem Cell Transplantation | In Situ Hybridization, Fluorescence | Nivolumab - therapeutic use | Enzyme Inhibitors - therapeutic use | Remission Induction | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Agents, Immunological - therapeutic use | Lenalidomide - therapeutic use | Protein Kinase Inhibitors - therapeutic use | para-Aminobenzoates - therapeutic use | Aniline Compounds - therapeutic use | Immunologic Factors - therapeutic use | Flow cytometry | Myeloid leukemia | Leukemia | Medical treatment | Health risks | Clinical trials | Transplantation | Patients | Hemopoiesis | Risk assessment | Cytogenetics | Remission | Acute myeloid leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Nature communications, ISSN 2041-1723, 02/2017, Volume 8, Issue 1, pp. 14293 - 14293
...), can be strong prognostic indicators. Here, we use optical tissue clearing and a TAM-targeting injectable fluorescent nanoparticle (NP... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Lung Neoplasms - drug therapy | Nanoparticles - chemistry | Humans | Carcinoma, Lewis Lung - immunology | Imaging, Three-Dimensional - methods | Lung Neoplasms - pathology | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Lung - diagnostic imaging | Aminopyridines - therapeutic use | Carcinoma, Lewis Lung - diagnostic imaging | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - immunology | Female | Antineoplastic Agents - pharmacology | Pyrroles - therapeutic use | Macrophages - immunology | Tumor Microenvironment - drug effects | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - antagonists & inhibitors | Lung - pathology | Mice, Inbred C57BL | Treatment Outcome | Macrophage Colony-Stimulating Factor - metabolism | Microscopy, Confocal - methods | Carcinoma, Lewis Lung - drug therapy | Macrophage Colony-Stimulating Factor - immunology | Tumor Microenvironment - immunology | Xenograft Model Antitumor Assays | Perfusion - methods | Lung Neoplasms - immunology | Pyrroles - pharmacology | Animals | Microscopy, Fluorescence - methods | Signal Transduction - drug effects | Tumor Burden - drug effects | Aminopyridines - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Line, Tumor | Lung Neoplasms - diagnostic imaging | Macrophages - drug effects | RAW 264.7 Cells | Mice | Nanoparticles - administration & dosage | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - metabolism | Tumor Burden - immunology | Index Medicus
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 08/2017, Volume 24, Issue 28, pp. 3054 - 3067
Phosphodiesterase (PDE) 4 is a superfamily of enzymes that catalyze the hydrolysis of cyclic adenosine 3', 5'-monophosphate (cAMP), an intracellular second... 
Autoimmunity | Psoriasis | Bregs | Tregs | Apremilast | cAMP | Psoriatic arthritis | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Eye Diseases - immunology | Humans | Autoimmune Diseases - immunology | Intestinal Diseases - drug therapy | Phosphodiesterase 4 Inhibitors - therapeutic use | Skin Diseases - drug therapy | Skin Diseases - immunology | Intestinal Diseases - immunology | Cyclopropanes - therapeutic use | Thalidomide - analogs & derivatives | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Eye Diseases - drug therapy | Thalidomide - therapeutic use | Autoimmune Diseases - drug therapy | Boron Compounds - therapeutic use | Immunologic Factors - therapeutic use | Multiple sclerosis | Inflammatory bowel diseases | Genes | Helper cells | Leukocytes (mononuclear) | Lymphocytes T | Arthritis | Dermatitis | Proteins | Vasculitis | Lymphocytes | Intestine | Atopic dermatitis | Chronic obstructive pulmonary disease | NF-κB protein | Immunoregulation | Lung diseases | Cyclic AMP | Pharmacology | CD3 antigen | Chemical compounds | Interleukin 17 | Mode of action | Chronic conditions | Inhibitors | Alopecia | Lymphocytes B | Rheumatoid arthritis | γ-Interferon | Interleukin 10 | Intracellular | Autoimmune diseases
Journal Article
The Lancet (British edition), ISSN 0140-6736, 03/2015, Volume 385, Issue 9971, pp. 857 - 866
Journal Article